Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outcry over REACH from beyond the EU

This article was originally published in Clinica

Executive Summary

The contents of the EU's proposed chemicals Regulation, REACH, has caused outrage beyond the EU's borders. Both the authorisation and registration rules have been heavily criticised by a coalition of states, including the US, Brazil and India, who are particularly concerned about the impact of REACH, particularly on SMEs - and especially on manufacturers from developing countries. The coalition, which also includes Japan, Australia, Korea, Malaysia, Singapore, Thailand, Mexico, South Africa, Israel and Chile, is calling on the EU to "use the second reading in Parliament to address the problematic aspects of the proposal".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel